ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None202420232022202120202019 Date Title 20 December 2024 Appendix 3Y for Eric Rose 20 December 2024 Application for quotation of securities - MSB 20 December 2024 Cleansing Notice 19 December 2024 Mesoblast Webcast 19 December 2024 FDA Approves Mesoblast Ryoncil 18 December 2024 Mesoblast to be Added to Nasdaq Biotechnology Index 18 December 2024 Ceasing to be a substantial holder 16 December 2024 Change in substantial holding 05 December 2024 Material Announcement 05 December 2024 Pause in Trade 05 December 2024 FDA Grants Mesoblast RMAT Designation 03 December 2024 REVASCOR Improves Survival & Reduces Major Morbidity 21 November 2024 Becoming a substantial holder 15 November 2024 Results of Meeting 15 November 2024 Final Director's Interest Notice 15 November 2024 CEO Presentation to 2024 Annual General Meeting 15 November 2024 Mesoblast Chair Message to 2024 AGM 14 November 2024 Response to ASX Price Query 12 November 2024 Notification regarding unquoted securities - MSB 07 November 2024 Warrant Prospectus Related to Convertible Note Agreement 05 November 2024 Ceasing to be a substantial holder 31 October 2024 Quarterly Activities/Appendix 4C Cash Flow Report 17 October 2024 Annual Report to Shareholders 17 October 2024 Notice of Annual General Meeting and Proxy Form 17 October 2024 Appendix 4G and Corporate Governance Statement 11 October 2024 Notification of cessation of securities - MSB 11 October 2024 Notification regarding unquoted securities - MSB 10 October 2024 Change in substantial holding 09 October 2024 Becoming a substantial holder 30 September 2024 Proposed issue of securities - MSB 30 September 2024 Mesoblast Option to Issue up to US$50m Convertible Notes 27 September 2024 Ceasing to be a substantial holder 17 September 2024 Becoming a substantial holder 29 August 2024 MSB Annual Financial Results and Operational Update 29 August 2024 Annual Financial Results Presentation 29 August 2024 Preliminary Final Report including Appendix 4E 28 August 2024 Mesoblast 2024 Full Year Financial Results Webcast 21 August 2024 Class Action Resolution 31 July 2024 Quarterly Activities/Appendix 4C Cash Flow Report 23 July 2024 FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L 22 July 2024 Confirmatory Phase 3 Back Pain Trial Actively Enrols 12 July 2024 Appendix 3Y for Philip Krause 12 July 2024 Notification regarding unquoted securities - MSB 12 July 2024 Notification of cessation of securities - MSB 12 July 2024 Change in substantial holding 09 July 2024 Mesoblast Resubmits BLA with FDA for Ryoncil Approval 01 July 2024 Mesoblast to File BLA for Ryoncil FDA Approval Next Week 03 June 2024 Mesoblast Corporate Presentation at Investor Conference 03 June 2024 Corporate Presentation 10 May 2024 Appendix 3Y for Eric Rose 03 May 2024 Appendix 3Y for Eric Rose 02 May 2024 Change in substantial holding 30 April 2024 Quarterly Activities/Appendix 4C Cash Flow Report 30 April 2024 Mesoblast Chair Transition 16 April 2024 Appendix 3Y for Jane Bell 16 April 2024 Application for quotation of securities - MSB 16 April 2024 Notification regarding unquoted securities - MSB 15 April 2024 Notification of cessation of securities - MSB 09 April 2024 Change in substantial holding 02 April 2024 Change in substantial holding 26 March 2024 FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA 26 March 2024 Pause in Trading 26 March 2024 Cleansing Notice 22 March 2024 Application for quotation of securities - MSB 20 March 2024 Change in substantial holding 20 March 2024 Proposed issue of securities - MSB 19 March 2024 Cleansing Notice 18 March 2024 Appendix 2A 14 March 2024 Proposed issue of securities - MSB 14 March 2024 Mesoblast Completes Placement and Entitlement Offer 11 March 2024 FDA Supports Accelerated Approval Pathway for Heart Failure 29 February 2024 MSB Q2 Financial Results and Operational Highlights 29 February 2024 Half Year Financial Results Presentation 29 February 2024 Half Year Report and Accounts (including Appendix 4D) 26 February 2024 Mesoblast 2024 Half Year Financial Results Webcast 15 February 2024 FDA Grants Orphan Drug Designation for Revascor 31 January 2024 Quarterly Activities/Appendix 4C Cash Flow Report 19 January 2024 FDA Grants Rare Pediatric Disease Designation for Revascor 15 January 2024 App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina 15 January 2024 Notification regarding unquoted securities - MSB 15 January 2024 Notification of cessation of securities - MSB 04 January 2024 Appendix 3Y for Joseph Swedish 04 January 2024 Amended Appendix 3Gs for Unquoted Warrants
